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ABSTRACT 
Background: Elevated mean platelet volume (MPV) has been proposed as a risk factor for coronary artery disease 
(CAD) and is associated with poor clinical outcome in acute coronary syndrome (ACS). However some studies have 
contradictory findings. Hence we aimed to evaluate the association of MPV with presence of coronary collateral 
vessel (CCV) in patients with ACS. 
Objective: To find MPV value in ACS patients and to find predictive value of MPV in spectrum of CAD and to 
examine whether levels of MPV predict the presence of CCVs. 
Methods:  A total of 180 patients with first ACS were included in the study.  Mean platelet volume (MPV) was 
measured. All patients underwent coronary angiography to know disease severity and coronary collateral vessels 
(CCVs). The CCVs are graded according to the Rentrop scoring system and According to coronary angiography  
results, patients were divided into two groups as Group 1 (poor CCV) and Group 2 (good CCV). 
Results:  The mean MPV was  10.74 ± 2 fl in poor collaterals group patients and 11.01 ±1.7 fl in good collaterals 
group (p value 0.421). Presence of CCV was not significantly associated with high levels of MPV. MPV value did not 
show any prediction of spectrum of coronary artery disease. 
Conclusion: MPV on admission was not associated with development of CCV positively in patients with ACS. Also it 
is not associated with number of vessel involvements.  
KEYWORDS: Acute coronary syndrome; coronary artery disease; mean platelet volume; Coronary collateral 
vessels; rentrop criteria. 
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INTRODUCTION 
Acute coronary syndromes (ACS) are a set of signs and symptoms due to the rupture of a 
plaque and are a consequence of platelet-rich coronary thrombus formation. The thrombus 
leads to partial or complete coronary artery occlusion, which, in turn, leads to myocardial 
ischemia and various clinical manifestations ranging from unstable angina (UA) to acute 
myocardial infarction (AMI). Platelets play an important role in the pathophysiology of 
atherosclerosis and prothrombotic events leading to ACS.1 Platelets are heterogeneous with 
respect to their size and reactivity. Large platelets are metabolically and enzymatically more 
active than small ones and have higher thrombotic potential. Generalized platelet activation 
occurs during the acute coronary event, where the increase rate of platelet consumption at 
the site of atherosclerotic plaque rupture leads to the release of large size platelets from the 
bone marrow. This activation process results in signaling pathways that induce platelets to 
change their shape (metamorphosis) and size  and become more active in secreting 
thromboxane A2 and ADP into the circulation. Larger platelets are more adhesive and tend 
to aggregate more than smaller ones that contain more secretory granules and 
mitochondria and are known to be more active than smaller platelets. The release of 
thromboxane A2 and ADP also stimulates the neighboring platelets, causing them to 
become activated and in turn secrete additional thromboxane A2 and ADP. Activated large 
size platelets directly bind to the circulating coagulation protein fibrinogen, via the 
abundant platelet integrin, glycoprotein (GP) IIb/IIIa receptors. The platelet–fibrinogen–
platelet connection initiates the process of platelet aggregation and thus, leads to coronary 
thrombus formation.2 Mean platelet volume (MPV) is a useful biomarker of platelet 
activity.1-3 Increase in MPV is associated with poor clinical outcome and impaired 
angiographic reperfusion in patients with myocardial infarction (MI).4Therefore; MPV is a 
marker of platelet reactivity. Unlike all other markers of platelet activation and reactivity, it 
is automatically calculated by most equipment for performing blood-cell count. Thus, 
platelet size determination through MPV is a simple, extremely inexpensive, and readily 
available measure in hospital and outpatient settings. Coronary   collateral   vessels   (CCVs)   
circulation is a compensatory response to overcome injury in cases of severe ischemia 
secondary to tight stenosis or occluded vessels. Well developed coronary collaterals can 
provide a perfusion reserve in case of increased myocardial oxygen demand and preserve 
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ventricular function and viability, providing an alternative blood supply to an ischemic 
region in coronary artery disease. Prominent interindividual variability exists even among 
patients with similar degree of coronary artery disease.5 however, it remains unclear which 
factors are responsible for these differences 6. Several studies have shown that the 
development of CCs is impaired in the presence of many of the risk factors predisposing to 
atherosclerosis such as age, hypercholesterolemia, diabetes mellitus (DM) and smoking.7-14 
In addition, many serum biomarkers, such as high-sensitivity C-reactive protein (CRP), 
lipoprotein-associated phospholipase A2, paraoxonase activity and asymmetric 
dimethylarginine, have been reported to be associated with the development of CCs .12-15 
 The presence of CCV is correlated with well clinical outcomes in patients with 
ACS.16Although many studies have reported the role of mean platelet volume (MPV) in 
various cardiovascular diseases17 some studies suggested that increased MPV predicted the 
risk of coronary artery disease (CAD) and cardiac mortality.18 So our interest is whether 
increased MPV predict  the presence of collaterals, which is also a major predictor of 
mortality in ACS. Association of higher MPV values with collaterals in ACS has been mostly 
studied among western patients.19 A few reports have revealed larger MPV values in Indian 
patients with ACS20-21but no association of MPV with coronary collaterals is studied till now 
in Indian patients. In the present study,  Our aim was to find  MPV value in ACS patients and 
to  find predictive value of MPV in spectrum of CAD and to examine whether levels of MPV 




A total of 180 consecutive patients who were admitted to hospital with first episode of ACS 
were prospectively included in the study. Patients who underwent coronary angiography at 
the Department of Cardiology, SMS Hospital, Jaipur) between January 2015 and June 2015 
were evaluated. Demographic and clinical data were obtained from the patients’ medical 
records and detailed history.  DM was defined as a history of DM, the use of antidiabetic 
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drugs or fasting plasma glucose levels of ≥7 mmol/L. Hypertension (HTN) was defined as a 
history of HTN or use of antihypertensive drugs, or a blood pressure ≥140/90 mmHg. 
Smoking status was defined as current smoking. The study protocol was approved by the 
local ethics committee. Patients with hepatic or renal dysfunction (serum creatinine level 
>2mg/dl), previous ACS patients, previous revascularization (coronary artery bypass graft 
operation or percutaneous coronary intervention) history, severe valvular disease, 
myocardial or pericardial disease, and technically inadequate coronary angiography were 
excluded from the study. Patients who were diagnosed with hematological disease, cancer, 
systemic inflammatory or autoimmune disease, thrombocytopenia and the use of 
anticoagulant agents were also excluded from the present study. Sample size was calculated 
to allow detection of a 30% difference in MPV between different groups and with α of .05 
and power of 80 %. Total 180 subjects were recruited and studied in two groups.   According 
to coronary angiography results, patients were divided into two groups as Group 1 (poor 
CCV) and Group 2 (good CCV).Informed consent was obtained from all patients. The study 
was approved by our local ethics committee. 
Laboratory Analysis 
In all cases, venous blood samples were drawn at admission before starting any medication. 
Serum glucose, blood urea, serum creatinine, were measured by standard methods. 
Tripotassium ethylenediaminetetraacetic acid (EDTA) based anticoagulated blood samples 
were drawn and assessed using the Beckman Coulter LH 750 and Hmx systems (Beckman 
Coulter, USA) using original reagents. Hemoglobin, platelet count, white blood cell (WBC) 
count   and mean platelet volume were analyzed using a blood counter (Sysmex 4000 
Roche, Mannheim, Germany) that measures platelet size using aperture-impedance 
technology. All patient samples were processed within 2 hours after venipuncture as 
recommended in the literature17 to avoid bias due to excessive platelet swelling .The 
expected values for MPV in our laboratory ranged from 7.0 to 10.5 fl. A high MPV was 
defined as a value ≥10.5 fl. 
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Angiographic Evaluation and CC Grading 
Coronary angiography was performed using standard techniques (Siemens Axiom Artis zee, 
Siemens Healthcare, Erlangen, Germany). Coronary angiography was performed through the 
femoral artery or radial artery for all patients using the Judkin technique. Each angiogram 
was interpreted by two experienced cardiologists who were blinded to the clinical details 
and results of the other investigations of each patient. Coronary collaterals vessels were 
graded according to the Rentrop grading system of 0 to 3: 0 = no filling of any collateral 
vessel; 1 = filling of the side branches of the artery to be perfused by collateral vessels 
without visualization of the epicardial segment; 2 = partial filling of the distal epicardial 
segment by collateral vessels; and 3 = complete filling of the distal epicardial segment by 
collateral vessels 
22
. The vessel that had the highest Rentrop grade with collaterals was used 
for analysis when more than one occluded vessel was present. In cases for which more than 
one collateral vessel to the same occluded vessel was present, the highest Rentrop grade 
was used. Rentrop grade 0 accepted as no development of CCV and Rentrop Grade ≥1 was 
accepted as presence of CCV .The study population was divided into two groups according 
to the Rentrop collateral score. Patients with grade 0 to 1 collateral development were 
classified as the poor collateral group; and patients with Rentrop grade 2 to 3 collateral 
development were classified as the good collateral group.  
Statistical Analysis 
All analyses were performed using SPSS V 16.0 for windows (version 16.0, SPSS, Chicago, IL, 
USA). Quantitative variables were expressed as mean value ± SD. Comparison of 
quantitative variables between two groups was performed by means samples t test. 
Categorical variables were compared by the chi-square test. P-value < 0.05 was considered 
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1. Table 1 shows baseline clinical characteristics of the patients. 
2. Tables 2 and 3 show the relation between the presence of CCV and baseline clinical 
and laboratory characteristics of the patients. The mean platelet count was 218.6 ± 
98.4(×103) in poor collateral group patients and 206.3 ±76.53 (103) in good 
collaterals group patients.(p value 0.447).there was  also no correlation of platelet 
counts with mean platelet volume.  The mean MPV was 10.74 ± 2 fl in poor 
collaterals group patients and 11.01 ±1.7 fl in good collaterals group (p value 0.421) . 
Presence of CCV was not significantly associated with high levels of MPV (p = 0.421). 
3. Table 3 also MPV value did not show any prediction of spectrum of coronary artery 
disease .Mean platelet volume was not significantly different in number of vessel 
involvement (single vessel disease v/s double vessel disease v/s triple vessel 
disease). Mean age was 58.34± 11.04 years in poor collaterals group and 57.36±8.5 
in good collaterals group. Rentrop 0, 1, 2, and 3 were determined in (table 4 and 
figure1), 102 (56.66 %), 34 (18.88 %), 30 (16.66%), and 14 (7.77 %) patients 
respectively. Rentrop 0-1 (poor collaterals group) were determined in 136 (75.5 %) 
patients. There was no significant difference in MPV value in rentrop score. Mean 
MPV value was 11.33 ±1.23 in normal coronaries patients while in coronary artery 
disease patients Mean MPV value was 10.77±1.96 (p value 0.325). Mean MPV value 
was not different in diabetic patients from non diabetic patients. 
 
DISCUSSION 
Previous studies showed Effect of platelet volume on coronary adverse outcomes. 
1–4
Well-
developed CCs are important compensatory mechanisms in the protection of myocardium 
in the ischemic region during coronary occlusion. The factors involved in the development of 
CCs have been investigated in numerous studies. Several demographic, clinical and 
biochemical factors have been reported to be associated with the degree of CC 
development.
7-15
However, there are insufficient data regarding the relation between MPV 
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and CCV. Well developed CCVs can limit myocardial ischemia, may minimize the infarct size, 
and can protect the viable myocardium in patients with ACS.
5–8
The absence of CCV is 
correlated with bad clinical outcomes in patients with ACS.
23
 Resting distal coronary 
pressure consistently falls as stenosis severity exceeds 70%.
23
 Although the underlying 
mechanism remains uncharacterized, myocardial ischemia, growth factors [such as 
fibroblast growth factor (FGF) and vascular endothelial growth factor], various cells such as 
endothelial, monocytes, smooth muscle, cytokines, and shear stress are likely factors that 
contribute to initiating and remodeling for collateral development during tissue hypoxia.
24-
27
Endothelial dysfunction is associated with poorer collateral growth
28
 Also duration of 
angina pectoris and the extent  of  CAD are well-established determinants of CCVs
29
 
Platelets play a key role in the pathogenesis, morbidity, and mortality of ACS
30
Increase in 
platelet activation is associated with CAD, carotid artery disease, and transplant 
vasculopathy
31-34
Elevated MPV has been recognized as an independent risk factor for MI
35
 
Large platelets are metabolically and enzymatically more active than smaller ones and 
secrete and express more mediators such as adhesive proteins (fibrinogen, 
thrombospondin, and fibronectin), growth factors [platelet-derived growth factor (PDGF), 
transforming growth factor-β, basic FGF], chemotactic and mitogenic factors [platelet factor 
4 (PF4), coagulation factors (factor V, factor XI), and cytokine-like factors (interleukin-1, 
CD40 ligand)]
36-38
Chemokines that are secreted from active platelets also stimulate smooth 
muscle cells and contribute to inflammation and atherogenesis
37
Inflammatory markers  may 
also contribute to absence of CCV via endothelial dysfunction39However some studies 
showed  High MPV on admission was associated with presence of CCV in patients with 
ACS.
40,41
Howecer some other studies suggest opposite effect.42,43Recently,Egeetal. reported 
that MPV levels were significantly higher and Gensini score was significantly lower in the 
patients who had inadequate CCV in patients with CAD 
43
In another study, high MPV levels 
were associated with severe coronary artery disease but not associated with development 
of coronary collaterals.44 In our study, we found that high levels of MPV were not associated 
with the presence of CCV in patients with ACS.  
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Between MPV and known ischemic heart disease risk factors .We did not find any 
association between development of CCV and age, hypertension, smoking, or gender. In our 
study  there were not a sufficient Previous reports showed that there is a close relationship 
between MPV and other prognostic factors, such as smoking, diabetes and 
hypertension
(45,46)
 But our study showed no clear association number of  patients of risk 
factors  to assess the impact of  these factors  on the presence of collaterals. Thus, it is not 
possible to determine the effects of prognostic factors on the presence of collaterals 
according to the results of this study. Although the mechanism is still unclear, the increased 
megakaryocyte ploidy is positively and number of megakaryocytes is negatively correlated 
with platelet volume.
4 
Our study showed no association between elevated MPV and the 
total platelet count. Our study group includes only patients with ACS. We know that 
collaterals take time to develop but some studies showed early angiographic evidence of 
collateral circulation in patients with acute MI and non-ST elevation MI In our study means 
platelet volume was not significantly different in unstable angina from Non ST elevation 
myocardial infarction or ST elevation myocardial infarction. We did not find any correlation 
between coronary collaterals and acute coronary syndrome presentation. Patients with ACS 
and a well-developed collateral circulation may have profited from a gradually developing 
stenosis via slow growth of mural thrombi. Finally, different methods can be used to analyze 
platelet activation. All tests have some limitations. Thus MPV may provide an important, 
simple, effortless, and cost-effective marker which can be useful for evaluation of platelet 
activation but it is not predictive of development of Coronary collaterals. Nonetheless, 
conflicting results of other studies make this issue controversial, which warrants performing 
of more comprehensive studies in future. 
CONCLUSION 
MPV on admission was not associated with development of CCV positively in patients with 
ACS.  Also it is not associated with number of vessel involvements. 
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The present study had some limitations. First, the study population was relatively small. 
Second, inflammatory markers such as CRP and interleukin-6 were not analyzed. We did not 
quantify and compare CCs with invasive parameters other than the Rentrop scoring system. 
Patients with non-cardiac chest pain (atypical symptoms) might have unstable angina in the 
absence of electrocardiography changes and cardiac troponin positivity, have resulted in 
selection bias. Also there are no data about physical activity of the patients, which 
encourages the development of CCVs.  Angiographic techniques do not demonstrate vessels 
of which the luminal diameter is 1.0 mm or less. Finally Individuals were enrolled from a 
single interventional cardiology center. 
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